Preventing chemotherapy-induced nausea and vomiting: The economic implications of choosing antiemetics

Community Oncology

Volumn 2, Issue 2, 2005, Pages 127-132

  Vanscoy, Gordon J ^a,c   Fortner, Barry ^b,d   Smith, Randall ^c   Weber, Robert ^c   Rihn, Thomas L ^a,e  

^a Univ Pharmacotherapy Associates LLC   (United States)

^b Accelerated Community Oncology Research Network   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d West Clinic   (United States)

^e DUQUESNE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOLASETRON MESILATE; DOXORUBICIN; GRANISETRON; ONDANSETRON; PALONOSETRON; SEROTONIN 3 ANTAGONIST;

CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG CHOICE; ELECTRONIC MEDICAL RECORD; HEALTH CARE COST; HEALTH CARE QUALITY; HUMAN; MEDICARE; NAUSEA; REIMBURSEMENT; REVIEW;

EID: 15444380437     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1548-5315(11)70865-8     Document Type: Review

References (12)

1. Griffin AM, Butow PN, Coates AS, et al. On the receiving end, V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 1996;7:189-195.
2. Sun CC, Bodurka DC, Donato ML, et al. Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time? Gynecol Oncol 2002;87:118-128.
3. Sun CC, Bodurka DC, Weaver CB, et al. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 2004. Electronic publication ahead of print.
4. Osoba D, Zee B, Warr D, et al. Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. Support Care Cancer 1997;5:307-313.
5. Martin CG, Rubenstein EB, Elting LS, Kim YJ, Osoba D. Measuring chemotherapy-induced nausea and emesis. Cancer 2003;98:645-655.
6. Grunberg SM, Hansen M, Deuson RR, Mavros P, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 2004;100:2261-2268.
7. Eisenberg PD, Rubenstein EB, Cohen L, DeMoor C, Kim YJ, Grunberg SM. Perceptions and satisfaction (S) of oncologists (MDs) and oncology nurses (RNs) of antiemetic therapy (AET) for chemotherapy-induced nausea and vomiting (CINV) vs patient experiences after emetogenic chemotherapy (CT) in the US. Poster presented at the 39th Annual Meeting of the American Society of Clinical Oncology; May 31-June 3, 2003; Chicago, Ill. Abstract 2974.
8. DeMoor C, Cohen L, Eisenberg PD, Grunberg SM, Kim YJ, Rubenstein EB. Oncologists' compliance with antiemetic guidelines (AEg) and outcomes of patients receiving emetogenic chemotherapy (CT). Poster presented at the 39th Annual Meeting of the American Society of Clinical Oncology; May 31-June 3, 2003; Chicago, Ill. Abstract 2924.
9. Drummond M, O'Brien BJ, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. New York, NY: Oxford University Press; 1994.
10. Vanscoy G, Rubenstein E, Smith R, Weber R, Rihn T. Pharmacoeconomic analysis of palonosetron in patients receiving moderately emetogenic chemotherapy. Poster presented at The American Society of Health-System Pharmacists (ASHP) 39th Midyear Clinical Meeting; December 5-9, 2004; Orlando, Fla. Abstract P390E.
11. US Department of Labor Bureau of Labor Statistics. Consumer Price Indexes. Available at: http://www.bls.gov/cpi-home.htm. Accessed February 14, 2004.
12. Centers for Medicare & Medicaid Services (CMS), US Department of Health and Human Services. Medicare program: revisions to payment policies under the physician fee schedule for calendar year 2005. Final rule with comment period. Fed Regist 2004;69:66235-66915.